It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (BAL, an anti-PD-1 ...
GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...
US FDA grants breakthrough therapy designation to GSK’s Jemperli for locally advanced dMMR/MSI-H rectal cancer: London, UK Tuesday, December 17, 2024, 09:00 Hrs [IST] GSK plc an ...
NEW YORK – Ideaya Biosciences said on Monday that it plans to develop a KAT6/7 inhibitor, IDE251, as treatment for breast and lung cancer patients whose tumors harbor 8p11 amplifications.
The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting ...
London: GSK plc has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ...
triple negative breast cancer and microsatellite instability high cancers including colorectal and esophageal cancers. RP-1 is used to deliver certain optimized immune activating proteins directly ...
Findings seen in patients with microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancer ...